Sun Pharmaceutical Industries Ltd., currently in the eye of a storm over allegations of serious lapses in corporate governance practices, sought to address investor misgivings, generally claiming that it has played by the rule book, but indicating that it is open to reviewing certain operational aspects that may be making investors uncomfortable.
Sun’s defense came against a backdrop of allegations of governance deviations initially flagged by the Australian brokerage Macquarie and then...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

